Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Titania Holding AB (publ) | 253,235 | net | 14 Jul 2023 | tx 4+253,235 |
| Oasmia Pharmaceutical AB | 90,000 | net | 04 Dec 2019 | tx 2+90,000 |
| NCAB Group AB (publ) | 4,000 | net | 05 Jun 2018 | tx 1+4,000 |
| FasadgruppenGroup AB (publ) | 3,965 | net | 31 Mar 2026 | tx 1+3,965 |
| Atvexa AB | -2,500 | net | 11 Aug 2022 | tx 1−2,500 |
| Siljansvik AB | 2,500 | net | 24 Aug 2020 | tx 1+2,500 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 31 Mar 2026 | PURCHASE | FasadgruppenGroup AB (publ) | 3,965 | 15.00 SEK | first after silence |
| 14 Jul 2023 | GRANT_AWARD | Titania Holding AB (publ) | 100,000 | 1.01 SEK | deriv |
| 11 Aug 2022 | SALE | Atvexa AB | 2,500 | 88.00 SEK | |
| 16 Dec 2021 | PURCHASE | Titania Holding AB (publ) | 8,620 | 23.22 SEK | first after silence |
| 01 Nov 2021 | GRANT_AWARD | Titania Holding AB (publ) | 44,615 | 1.70 SEK | deriv |
| 24 Aug 2020 | PURCHASE | Siljansvik AB | 2,500 | 82.00 SEK | |
| 04 Dec 2019 | PURCHASE | Oasmia Pharmaceutical AB | 40,000 | 2.00 SEK | |
| 25 Nov 2019 | PURCHASE | Oasmia Pharmaceutical AB | 50,000 | 1.30 SEK | derivfirst after silence |
| 05 Jun 2018 | PURCHASE | NCAB Group AB (publ) | 4,000 | 75.00 SEK |
3 purchases reported after at least 12 months of silence — most recent on 31 Mar 2026.